 | | | | Shares of Intercept plunged 34.28% before the bell after the company said the agency found that the predicted effectiveness of the treatment is uncertain and does not sufficiently outweigh the potential risks. | | |
| | | Gilead Sciences Inc said on Monday it has priced its COVID-19 treatment candidate remdesivir at $390 per vial in the United States and other developed countries. | | |
| | | China reported 12 new confirmed COVID-19 cases as of end of June 28, down from 17 reported a day earlier as the country's capital tries to curb a new wave of infections that emerged from a wholesale market in mid-June. | | |
| | | Tokyo on Monday recorded 58 new cases of coronavirus infection, marking the fourth straight day that infections had exceeded 50, broadcaster TV Asahi reported. | | |
| | | A small study by researchers in Italy has found that COVID-19 patients who were tested for the novel coronavirus at a hospital there in May had fewer virus particles than those who were tested a month earlier. | | |
| | | The death toll from COVID-19 surpassed half a million people on Sunday, according to a Reuters tally, a grim milestone for the global pandemic that seems to be resurgent in some countries even as other regions are still grappling with the first wave. | | |
| | | Here's what you need to know about the coronavirus right now: | | |
| | | Qatar aims to further ease coronavirus curbs from July 1, allowing the limited reopening of restaurants, beaches and parks, as infections have passed their peak and the rate was subsiding, authorities said. | | |
| | | BioNTech said Singapore's Temasek and other investors are injecting $250 million into the German biotech firm through a private placement, reflecting heightened investor appetite for promising developers' vaccines against the coronavirus. | | |
| | | A shortage of test kits has undermined South Africa's early response to the coronavirus crisis, but a local biotechnology firm is stepping up to try plug the shortfall in testing capacity. | | |
| | | By Stephen Grey, Andrew MacAskill, Ryan McNeill, Steve Stecklow and Tommy Wilkes | | |
|
| |
